BindingDB logo
myBDB logout

327 articles for thisTarget

The following articles (labelled with PubMed ID or TBD) are for your review
PMIDDataArticle TitleOrganization
28088085 42 New pyridazinone-4-carboxamides as new cannabinoid receptor type-2 inverse agonists: Synthesis, pharmacological data and molecular docking.EBI University of Sassari
27876250 60 Structure-anticonvulsant activity studies in the group of (E)-N-cinnamoyl aminoalkanols derivatives monosubstituted in phenyl ring with 4-Cl, 4-CHEBI Jagiellonian University Medical College
27560280 138 Synthesis, binding assays, cytotoxic activity and docking studies of benzimidazole and benzothiophene derivatives with selective affinity for the CB2 cannabinoid receptor.EBI Pontificia Universidad Cat£lica de Chile
27448919 69 Discovery of novel Tetrahydrobenzo[b]thiophene and pyrrole based scaffolds as potent and selective CB2 receptor ligands: The structural elements controlling binding affinity, selectivity and functionality.EBI German University in Cairo
27671499 46 Tetrahydropyrazolo[4,3-c]pyridine derivatives as potent and peripherally selective cannabinoid-1 (CB1) receptor inverse agonists.EBI Janssen Research& Development, L.L.C.
27671496 46 Tetrahydroindazole derivatives as potent and peripherally selective cannabinoid-1 (CB1) receptor inverse agonists.EBI Janssen Research& Development, L.L.C.
27240274 37 A critical review of both the synthesis approach and the receptor profile of the 8-chloro-1-(2',4'-dichlorophenyl)-N-piperidin-1-yl-1,4,5,6-tetrahydrobenzo[6,7]cyclohepta[1,2-c]pyrazole-3-carboxamide and analogue derivatives.EBI Neuroscienze PharmaNess S.c.a r.l.
27096053 4 Discovery of KLS-13019, a Cannabidiol-Derived Neuroprotective Agent, with Improved Potency, Safety, and Permeability.EBI KannaLife Sciences
27078864 46 Synthesis and pharmacological evaluation of new biphenylic derivatives as CB2 receptor ligands.EBI Universit£ di Pisa
26888301 34 Development and Pharmacological Characterization of Selective Blockers of 2-Arachidonoyl Glycerol Degradation with Efficacy in Rodent Models of Multiple Sclerosis and Pain.EBI University of Siena
26876931 36 Optimization of N'-(arylsulfonyl)pyrazoline-1-carboxamidines by exploiting a novel interaction site in the 5-HT6 antagonistic binding pocket.EBI Abbott Healthcare Products B.V.
26789378 57 Identification of Novel GPR55 Modulators Using Cell-Impedance-Based Label-Free Technology.EBI Instituto de Qu£mica M£dica
26756097 56 Investigations on the 4-Quinolone-3-carboxylic Acid Motif. 7. Synthesis and Pharmacological Evaluation of 4-Quinolone-3-carboxamides and 4-Hydroxy-2-quinolone-3-carboxamides as High Affinity Cannabinoid Receptor 2 (CB2R) Ligands with Improved Aqueous Solubility.EBI Universit£ degli Studi di Siena
26988801 55 Design, physico-chemical properties and biological evaluation of some new N-[(phenoxy)alkyl]- and N-{2-[2-(phenoxy)ethoxy]ethyl}aminoalkanols as anticonvulsant agents.EBI Jagiellonian University Medical College
26890113 41 Tricyclic pyrazoles. Part 8. Synthesis, biological evaluation and modelling of tricyclic pyrazole carboxamides as potential CB2 receptor ligands with antagonist/inverse agonist properties.EBI Universit£ degli Studi di Sassari
26922225 91 Synthesis and structure activity relationship investigation of triazolo[1,5-a]pyrimidines as CB2 cannabinoid receptor inverse agonists.EBI Universit£ di Ferrara
26827137 26 Pyrazole antagonists of the CB1 receptor with reduced brain penetration.EBI RTI International
26209834 46 Synthesis, pharmacological evaluation and docking studies of pyrrole structure-based CB2 receptor antagonists.EBI Universit£ degli Studi di Sassari
26275680 68 Synthesis and biological evaluation of (3',5'-dichloro-2,6-dihydroxy-biphenyl-4-yl)-aryl/alkyl-methanone selective CB2 inverse agonist.EBI University of Tennessee Health Science Center
26149623 7 Combining Mass Spectrometric Metabolic Profiling with Genomic Analysis: A Powerful Approach for Discovering Natural Products from Cyanobacteria.EBI University of California Berkeley
26203658 39 Distinct Temporal Fingerprint for Cyclic Adenosine Monophosphate (cAMP) Signaling of Indole-2-carboxamides as Allosteric Modulators of the Cannabinoid Receptors.EBI University of Auckland
26151231 154 Development of Quinoline-2,4(1H,3H)-diones as Potent and Selective Ligands of the Cannabinoid Type 2 Receptor.EBI Zhejiang University
26000707 20 Isolation and Pharmacological Evaluation of Minor Cannabinoids from High-Potency Cannabis sativa.EBI The University of Mississippi
25466197 32 Novel azoles as potent and selective cannabinoid CB2 receptor agonists.EBI Ipsen Innovation
21511945 7 Cannabinoid type 1 receptor antagonists modulate transport activity of multidrug resistance-associated proteins MRP1, MRP2, MRP3, and MRP4.EBI Radboud University Nijmegen Medical Centre
25935384 26 New quinolone- and 1,8-naphthyridine-3-carboxamides as selective CB2 receptor agonists with anticancer and immuno-modulatory activity.EBI University of Pisa
25699149 52 Conformational Restriction Leading to a Selective CB2 Cannabinoid Receptor Agonist Orally Active Against Colitis.EBI Universit£ de Lille Nord de France
25671648 6 Selective, nontoxic CB(2) cannabinoid o-quinone with in vivo activity against triple-negative breast cancer.EBI Instituto de Qu£mica M£dica
25644673 186 Design, syntheses, structure-activity relationships and docking studies of coumarin derivatives as novel selective ligands for the CB2 receptor.EBI Zhejiang University
25599952 20 Synthesis, radiolabeling and evaluation of novel 4-oxo-quinoline derivatives as PET tracers for imaging cannabinoid type 2 receptor.EBI Institute of Pharmaceutical Sciences
25797163 34 Structure-activity relationships of substituted 1H-indole-2-carboxamides as CB1 receptor allosteric modulators.EBI Research Triangle Institute
25556098 36 Selective CB2 receptor agonists. Part 1: the identification of novel ligands through computer-aided drug design (CADD) approaches.EBI Boehringer Ingelheim Pharmaceuticals
25486424 30 Synthesis, biological activity and molecular modeling of new biphenylic carboxamides as potent and selective CB2 receptor ligands.EBI Universit£ di Pisa
25096297 63 Design, synthesis and in vitro evaluation of novel uni- and bivalent ligands for the cannabinoid receptor type 1 with variation of spacer length and structure.EBI Julius-Maximilians-Universit£t W£rzburg
25072877 40 One-pot heterogeneous synthesis of┐(3)-tetrahydrocannabinol analogues and xanthenes showing differential binding to CB(1) and CB(2) receptors.EBI University of Perugia
25065940 77 Structure-affinity relationships and pharmacological characterization of new alkyl-resorcinol cannabinoid receptor ligands: Identification of a dual cannabinoid receptor/TRPA1 channel agonist.EBI Universit£ degli Studi di Siena
24984935 24 Synthesis and biological evaluation of bivalent cannabinoid receptor ligands based on hCB2R selective benzimidazoles reveal unexpected intrinsic properties.EBI Julius-Maximilians-Universit£t W£rzburg
24972328 26 Identification of endocannabinoid system-modulating N-alkylamides from Heliopsis helianthoides var. scabra and Lepidium meyenii.EBI University of Szeged
24863744 15 DDD-028: a potent potential non-opioid, non-cannabinoid analgesic for neuropathic and inflammatory pain.EBI University of Missouri
23902803 9 Peripherally restricted CB1 receptor blockers.EBI Jenrin Discovery
25575658 83 Selective CB2 receptor agonists. Part 3: the optimization of a piperidine-based series that demonstrated efficacy in an in vivo neuropathic pain model.EBI Boehringer Ingelheim Pharmaceuticals
25556092 85 Selective CB2 receptor agonists. Part 2: Structure-activity relationship studies and optimization of proline-based compounds.EBI Boehringer Ingelheim Pharma GmbH& Co. KG
25499880 51 Identification of a highly potent and selective CB2 agonist, RQ-00202730, for the treatment of irritable bowel syndrome.EBI RaQualia Pharma Inc
25488844 154 Discovery of 1a,2,5,5a-tetrahydro-1H-2,3-diaza-cyclopropa[a]pentalen-4-carboxamides as potent and selective CB2 receptor agonists.EBI Arena Pharmaceuticals
25487422 93 Ligand-based virtual screening identifies a family of selective cannabinoid receptor 2 agonists.EBI University of Oxford
25466177 24 The SAR development of substituted purine derivatives as selective CB2 agonists for the treatment of chronic pain.EBI Lilly Research Laboratories
25272206 88 CB2-selective cannabinoid receptor ligands: synthesis, pharmacological evaluation, and molecular modeling investigation of 1,8-Naphthyridin-2(1H)-one-3-carboxamides.EBI Universit£ di Pisa
25241924 47 The design and implementation of a generic lipopeptide scanning platform to enable the identification of 'locally acting' agonists for the apelin receptor.EBI Novartis Institutes for BioMedical Research
25162172 51 Diarylureas as allosteric modulators of the cannabinoid CB1 receptor: structure-activity relationship studies on 1-(4-chlorophenyl)-3-{3-[6-(pyrrolidin-1-yl)pyridin-2-yl]phenyl}urea (PSNCBAM-1).EBI Research Triangle Institute
24922543 24 Tricyclic pyrazoles. Part 6. Benzofuro[3,2-c]pyrazole: a versatile architecture for CB2 selective ligands.EBI Universit£ di Sassari
24900877 107 Development of novel benzomorpholine class of diacylglycerol acyltransferase I inhibitors.EBI Merck Research Laboratories
24856183 4 Ultrapure ajulemic acid has improved CB2 selectivity with reduced CB1 activity.EBI Corbus Pharmaceuticals, Inc.
24731541 1 The cannabinoid acids, analogs and endogenous counterparts.EBI The University of Massachusetts Medical School
24182233 57 Reductions in log P improved protein binding and clearance predictions enabling the prospective design of cannabinoid receptor (CB1) antagonists with desired pharmacokinetic properties.EBI Bristol-Myers Squibb
23865723 338 Therapeutic utility of cannabinoid receptor type 2 (CB(2)) selective agonists.EBI Arena Pharmaceuticals
24461289 46 Benzimidazole CB2 agonists: design, synthesis and SAR.EBI Merck Research Laboratories
23621789 69 Novel adamantyl cannabinoids as CB1 receptor probes.EBI Northeastern University
23466226 26 Evaluation of (Z)-2-((1-benzyl-1H-indol-3-yl)methylene)-quinuclidin-3-one analogues as novel, high affinity ligands for CB1 and CB2 cannabinoid receptors.EBI University of Arkansas for Medical Sciences
23434135 27 Novel antiobesity agents: synthesis and pharmacological evaluation of analogues of Rimonabant and of LH21.EBI Instituto de Qu£mica M£dica
23380378 127 Highly potent and selective cannabinoid receptor 2 agonists: initial hit optimization of an adamantyl hit series identified from high-through-put screening.EBI F. Hoffmann-La Roche Ltd
24729834 79 Trisubstituted Sulfonamides: a New Chemotype for Development of Potent and Selective CBEBI University of Pittsburgh
24900561 25 Magnolia Extract, Magnolol, and Metabolites: Activation of Cannabinoid CB2 Receptors and Blockade of the Related GPR55.EBI University of Bonn
23406429 83 Novel triaryl sulfonamide derivatives as selective cannabinoid receptor 2 inverse agonists and osteoclast inhibitors: discovery, optimization, and biological evaluation.EBI University of Pittsburgh
23350768 196 Design, synthesis, and pharmacological properties of new heteroarylpyridine/heteroarylpyrimidine derivatives as CB(2) cannabinoid receptor partial agonists.EBI Universit£ di Ferrara
23227781 119 Discovery of agonists of cannabinoid receptor 1 with restricted central nervous system penetration aimed for treatment of gastroesophageal reflux disease.EBI AstraZeneca
17027269 23 Arylsulfonamides as a new class of cannabinoid CB1 receptor ligands: identification of a lead and initial SAR studies.EBI UCB S.A.
22548457 60 Design, synthesis, and pharmacological characterization of indol-3-ylacetamides, indol-3-yloxoacetamides, and indol-3-ylcarboxamides: potent and selective CB2 cannabinoid receptor inverse agonists.EBI Universit£ degli Studi di Siena
21334892 39 Pharmacokinetic optimisation of novel indole-2-carboxamide cannabinoid CB1 antagonists.EBI MSD
21316962 31 Discovery of potent and orally bioavailable heterocycle-based cannabinoid CB1 receptor agonists.EBI Merck Research Laboratories
20634067 23 Design, synthesis, and structure-activity relationship study of conformationally constrained analogs of indole-3-carboxamides as novel CB1 cannabinoid receptor agonists.EBI Schering-Plough Research Institute
20005703 66 Synthesis and evaluation of 3-amino-6-aryl-pyridazines as selective CB(2) agonists for the treatment of inflammatory pain.EBI GlaxoSmithKline
19864133 42 2-Amino-5-aryl-pyridines as selective CB2 agonists: synthesis and investigation of structure-activity relationships.EBI GlaxoSmithKline
19406638 35 Predictive models of Cannabinoid-1 receptor antagonists derived from diverse classes.EBI Korea Research Institute of Chemical Technology
23147076 163 Structure-activity relationships of 2-arylamido-5,7-dihydro-4H-thieno[2,3-c]pyran-3-carboxamide derivatives as cannabinoid receptor agonists and their analgesic action.EBI Nycomed Pharma Pvt. Ltd
22341572 61 Synthesis and pharmacology of 1-alkyl-3-(1-naphthoyl)indoles: steric and electronic effects of 4- and 8-halogenated naphthoyl substituents.EBI RTI International
23098108 36 Diphenyl purine derivatives as peripherally selective cannabinoid receptor 1 antagonists.EBI Research Triangle Institute
23072339 132 Lead discovery, chemistry optimization, and biological evaluation studies of novel biamide derivatives as CB2 receptor inverse agonists and osteoclast inhibitors.EBI University of Pittsburgh
22916707 76 7-Alkyl-3-benzylcoumarins: a versatile scaffold for the development of potent and selective cannabinoid receptor agonists and antagonists.EBI University of Bonn
23017078 62 4-Oxo-1,4-dihydropyridines as selective CB2 cannabinoid receptor ligands. Part 2: discovery of new agonists endowed with protective effect against experimental colitis.EBI Universit£ Lille Nord de France
22738271 250 7-Oxo-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxamides as selective CB(2) cannabinoid receptor ligands: structural investigations around a novel class of full agonists.EBI Universit£ di Ferrara
23164658 78 2-Arylbenzofuran-based molecules as multipotent Alzheimer's disease modifying agents.EBI University of Bologna
23151320 37 Scaffold hopping strategy toward original pyrazolines as selective CB2 receptor ligands.EBI Avenue de l'Universit£
23085772 82 Investigations on the 4-quinolone-3-carboxylic acid motif. 6. Synthesis and pharmacological evaluation of 7-substituted quinolone-3-carboxamide derivatives as high affinity ligands for cannabinoid receptors.EBI Universit£ degli Studi di Siena
22959249 79 JD-5006 and JD-5037: peripherally restricted (PR) cannabinoid-1 receptor blockers related to SLV-319 (Ibipinabant) as metabolic disorder therapeutics devoid of CNS liabilities.EBI Jenrin Discovery
22832315 85 Structure and activity relationship in the (S)-N-chroman-3-ylcarboxamide series of voltage-gated sodium channel blockers.EBI AstraZeneca
22571451 46 Indole-2-carboxamides as allosteric modulators of the cannabinoid CB1 receptor.EBI Sapienza Universit£ di Roma
24900484 64 Design of a Potent CB1 Receptor Antagonist Series: Potential Scaffold for Peripherally-Targeted Agents.EBI TBA
22765893 32 Discovery and optimization of novel purines as potent and selective CB2 agonists.EBI Lilly Research Laboratories
22607668 66 N-Methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-1H-carbazole-6-carboxamides as a novel class of cannabinoid receptors agonists with low CNS penetration.EBI AstraZeneca
22372835 71 Design and synthesis of cannabinoid receptor 1 antagonists for peripheral selectivity.EBI Research Triangle Institute
22421019 62 Discovery of S-444823, a potent CB1/CB2 dual agonist as an antipruritic agent.EBI Shionogi& Co., Ltd
24900275 1 Identification of a Potent and Selective Cannabinoid CB1 Receptor Antagonist from Auxarthron reticulatum.EBI TBA
24936232 16 Discovery of Potent Dual PPARa Agonists/CB1 Ligands.EBI TBA
22483967 38 Rational design, synthesis and anti-proliferative properties of new CB2 selective cannabinoid receptor ligands: an investigation of the 1,8-naphthyridin-2(1H)-one scaffold.EBI Universit£ di Pisa
22444677 45 Discovery of S-777469: an orally available CB2 agonist as an antipruritic agent.EBI Shionogi& Co., Ltd
22437111 34 CB 1/2 dual agonists with 3-carbamoyl 2-pyridone derivatives as antipruritics: reduction of CNS side effects by introducing polar functional groups.EBI Shionogi& Co., Ltd.
22421020 9 Low brain penetrant CB1 receptor agonists for the treatment of neuropathic pain.EBI Merck Research Laboratories
22370265 63 Synthesis and evaluation of 2-amido-3-carboxamide thiophene CB2 receptor agonists for pain management.EBI Abbott Laboratories
21428406 70 N-(4-cyanotetrahydro-2H-pyran-4-yl) and N-(1-cyanocyclohexyl) derivatives of 1,5-diarylpyrazole-3-carboxamides showing high affinity for 18 kDa translocator protein and/or cannabinoid receptors.EBI National Institute of Mental Health
20875743 90 Discovery of {1-[4-(2-{hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl}-1H-benzimidazol-1-yl)piperidin-1-yl]cyclooctyl}methanol, systemically potent novel non-peptide agonist of nociceptin/orphanin FQ receptor as analgesic for the treatment of neuropathic pain: design, synthesis, and structure-activity relaEBI Pfizer Inc.
20943404 24 1-Bromo-3-(1',1'-dimethylalkyl)-1-deoxy-¿(8)-tetrahydrocannabinols: New selective ligands for the cannabinoid CB(2) receptor.EBI Clemson University
20684563 176 Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 receptor agonist with unprecedented selectivity and procognitive potential.EBI H. Lundbeck A/S
20718492 74 Investigations on the 4-quinolone-3-carboxylic acid motif. 3. Synthesis, structure-affinity relationships, and pharmacological characterization of 6-substituted 4-quinolone-3-carboxamides as highly selective cannabinoid-2 receptor ligands.EBI Universit£ degli Studi di Siena
20363132 34 Probing the cannabinoid CB1/CB2 receptor subtype selectivity limits of 1,2-diarylimidazole-4-carboxamides by fine-tuning their 5-substitution pattern.EBI Solvay Pharma
20137935 46 Synthesis, SAR and intramolecular hydrogen bonding pattern of 1,3,5-trisubstituted 4,5-dihydropyrazoles as potent cannabinoid CB(1) receptor antagonists.EBI Solvay Pharma
20031412 36 Synthesis and SAR of novel imidazoles as potent and selective cannabinoid CB2 receptor antagonists with high binding efficiencies.EBI Solvay Pharma
20018510 73 Diaryl piperidines as CB1 receptor antagonists.EBI Merck Research Laboratories
19595596 114 Synthesis, cannabinoid receptor affinity, molecular modeling studies and in vivo pharmacological evaluation of new substituted 1-aryl-5-(1H-pyrrol-1-yl)-1H-pyrazole-3-carboxamides. 2. Effect of the 3-carboxamide substituent on the affinity and selectivity profile.EBI Sapienza Universit£ di Roma
19520572 55 Discovery and functional evaluation of diverse novel human CB(1) receptor ligands.EBI Vernalis (R&D) Ltd
19435366 34 Rational design, synthesis, and pharmacological properties of new 1,8-naphthyridin-2(1H)-on-3-carboxamide derivatives as highly selective cannabinoid-2 receptor agonists.EBI Universita di Pisa
19278853 67 Synthesis and pharmacological evaluation of coumarin derivatives as cannabinoid receptor antagonists and inverse agonists.EBI University of Bonn
19143566 52 Discovery of novel CB2 receptor ligands by a pharmacophore-based virtual screening workflow.EBI University of Innsbruck
19115816 38 6-Methoxy-N-alkyl isatin acylhydrazone derivatives as a novel series of potent selective cannabinoid receptor 2 inverse agonists: design, synthesis, and binding mode prediction.EBI The University of Texas M. D. Anderson Cancer Center
18680277 198 Discovery and optimization of a novel series of N-arylamide oxadiazoles as potent, highly selective and orally bioavailable cannabinoid receptor 2 (CB2) agonists.EBI Amgen Inc.
18680276 46 Investigations on the 4-quinolone-3-carboxylic acid motif. 2. Synthesis and structure-activity relationship of potent and selective cannabinoid-2 receptor agonists endowed with analgesic activity in vivo.EBI Universit£ degli Studi di Siena
18666769 32 Design and synthesis of a novel series of N-alkyl isatin acylhydrazone derivatives that act as selective cannabinoid receptor 2 agonists for the treatment of neuropathic pain.EBI The University of Texas M. D. Anderson Cancer Center
18579386 40 Novel sterically hindered cannabinoid CB1 receptor ligands.EBI University of Salerno
16562853 22 Alkaloids from Eschscholzia californica and their capacity to inhibit binding of [3H]8-Hydroxy-2-(di-N-propylamino)tetralin to 5-HT1A receptors in Vitro.EBI Tom's of Maine
18448340 27 Aminopyrazine CB1 receptor inverse agonists.EBI Neurogen Corporation
18440813 55 The SAR studies of novel CB2 selective agonists, benzimidazolone derivatives.EBI Pfizer Inc.
18430570 76 Sulfamoyl benzamides as novel CB2 cannabinoid receptor ligands.EBI Adolor Corporation
18424134 114 New tetrazole-based selective anandamide uptake inhibitors.EBI Sapienza Universit£ di Roma
18006322 43 Imine derivatives as new potent and selective CB2 cannabinoid receptor agonists with an analgesic action.EBI Taisho Pharmaceutical Co., Ltd
18333607 4 Conformational analysis and receptor docking of N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-{[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (taranabant, MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist.EBI Merck Research Laboratories
17483457 58 A-803467, a potent and selective Nav1.8 sodium channel blocker, attenuates neuropathic and inflammatory pain in the rat.EBI Abbott Laboratories
17942307 34 New 1,8-naphthyridine and quinoline derivatives as CB2 selective agonists.EBI Universit£ di Pisa
17884496 51 N-Alkylidenearylcarboxamides as new potent and selective CB(2) cannabinoid receptor agonists with good oral bioavailability.EBI Taisho Pharmaceutical Co. Ltd
17630726 32 Naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone: a potent, orally bioavailable human CB1/CB2 dual agonist with antihyperalgesic properties and restricted central nervous system penetration.EBI Novartis Institutes for BioMedical Research
17561406 67 Design, synthesis, binding, and molecular modeling studies of new potent ligands of cannabinoid receptors.EBI Universit£ degli Studi di Siena
16279809 23 1-Benzhydryl-3-phenylurea and 1-benzhydryl-3-phenylthiourea derivatives: new templates among the CB1 cannabinoid receptor inverse agonists.EBI Universit£ catholique de Louvain
16279794 46 Design, synthesis, and binding studies of new potent ligands of cannabinoid receptors.EBI Universit£ degli Studi di Siena
17181138 27 Discovery of N-[(1S,2S)-3-(4-Chlorophenyl)-2- (3-cyanophenyl)-1-methylpropyl]-2-methyl-2- {[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist for the treatment of obesity.EBI Merck Research Laboratories
16451053 37 Synthesis and activity of 1,3,5-triphenylimidazolidine-2,4-diones and 1,3,5-triphenyl-2-thioxoimidazolidin-4-ones: characterization of new CB1 cannabinoid receptor inverse agonists/antagonists.EBI Universit£ catholique de Louvain
16392793 42 Novel 4-oxo-1,4-dihydroquinoline-3-carboxamide derivatives as new CB2 cannabinoid receptors agonists: synthesis, pharmacological properties and molecular modeling.EBI Universit£ de Lille 2
16213718 93 New metabolically stable fatty acid amide ligands of cannabinoid receptors: Synthesis and receptor affinity studies.EBI Institute of Biomolecular Chemistry
16140010 32 Novel 3,4-diarylpyrazolines as potent cannabinoid CB1 receptor antagonists with lower lipophilicity.EBI Solvay Pharma
15771428 66 Bioisosteric replacements of the pyrazole moiety of rimonabant: synthesis, biological properties, and molecular modeling investigations of thiazoles, triazoles, and imidazoles as potent and selective CB1 cannabinoid receptor antagonists.EBI Solvay Pharma
16078824 48 The endocannabinoid system: drug targets, lead compounds, and potential therapeutic applications.EBI Universit£ Catholique de Louvain
12747783 17 Rational design and synthesis of an orally active indolopyridone as a novel conformationally constrained cannabinoid ligand possessing antiinflammatory properties.EBI Bristol-Myers Squibb
11960486 6 Exploration of the pharmacophore of 3-alkyl-5-arylimidazolidinediones as new CB(1) cannabinoid receptor ligands and potential antagonists: synthesis, lipophilicity, affinity, and molecular modeling.EBI Universit£ de Lausanne
11585444 295 From hit to lead. Analyzing structure-profile relationships.EBI F-59000 Lille
9857088 16 The bioactive conformation of aminoalkylindoles at the cannabinoid CB1 and CB2 receptors: insights gained from (E)- and (Z)-naphthylidene indenes.EBI Kennesaw State University
9784115 15 Potent cyano and carboxamido side-chain analogues of 1', 1'-dimethyl-delta8-tetrahydrocannabinol.EBI Organix, Inc.
9057852 74 Structural requirements for binding of anandamide-type compounds to the brain cannabinoid receptor.EBI Hebrew University
10465552 10 3-Alkyl-(5,5'-diphenyl)imidazolidineiones as new cannabinoid receptor ligands.EBI Universit£ Catholiqu£ de Louvain
22284817 82 ¿-Carbolines: a novel class of cannabinoid agonists with high aqueous solubility and restricted CNS penetration.EBI AstraZeneca R&D Montreal
22209458 114 Fatty acid amide hydrolase inhibitors. 3: tetra-substituted azetidine ureas with in vivo activity.EBI Vernalis (R&D) Ltd
22130134 58 5-sulfonyl-benzimidazoles as selective CB2 agonists-part 2.EBI Janssen Research& Development
22172309 12 Novel bioactive metabolites of dipyrone (metamizol).EBI Philipps-Universit£t
21999614 11 Cannabinomimetic lipid from a marine cyanobacterium.EBI University of California
22044209 56 Resorcinol-sn-glycerol derivatives: novel 2-arachidonoylglycerol mimetics endowed with high affinity and selectivity for cannabinoid type 1 receptor.EBI Universit£ degli Studi di Siena
21996466 40 1-Aryl-5-(1H-pyrrol-1-yl)-1H-pyrazole-3-carboxamide: an effective scaffold for the design of either CB1 or CB2 receptor ligands.EBI Sapienza Universit£ di Roma
21962575 8 Characterization of a novel and selective CB1 antagonist as a radioligand for receptor occupancy studies.EBI Bristol-Myers Squibb Co.
21937154 9 Asymmetric synthesis and biological evaluation of N-cyclohexyl-4-[1-(2,4-dichlorophenyl)-1-(p-tolyl)methyl]piperazine-1-carboxamide as hCB1 receptor antagonists.EBI Shanghai Institute of Materia Medica
21880487 21 Conformationally constrained analogs of BAY 59-3074 as novel cannabinoid receptor ligands.EBI Northeastern University
21875798 30 Towards rational design of cannabinoid receptor 1 (CB1) antagonists for peripheral selectivity.EBI RTI International
21835510 14 Homology modeling in tandem with 3D-QSAR analyses: a computational approach to depict the agonist binding site of the human CB2 receptor.EBI Universit£ di Genova
21902175 24 Bioactive prenylogous cannabinoid from fiber hemp (Cannabis sativa).EBI Universita` del Piemonte Orientale
21872477 43 Fluorinated cannabinoid CB2 receptor ligands: synthesis and in vitro binding characteristics of 2-oxoquinoline derivatives.EBI The University of Texas
21702498 34 Investigations on the 4-quinolone-3-carboxylic acid motif. 4. Identification of new potent and selective ligands for the cannabinoid type 2 receptor with diverse substitution patterns and antihyperalgesic effects in mice.EBI Universita degli Studi di Siena
21667972 5 Benzyl derivatives with in vitro binding affinity for human opioid and cannabinoid receptors from the fungus Eurotium repens.EBI The University of Mississippi
21737287 3 Synthesis, in vitro and in vivo evaluation of fluorine-18 labelled FE-GW405833 as a PET tracer for type 2 cannabinoid receptor imaging.EBI IMIR K.U. Leuven
20615693 37 Tricyclic imidazole antagonists of the Neuropeptide S Receptor.EBI Merck Research Laboratories
21675776 22 Development of endocannabinoid-based chemical probes for the study of cannabinoid receptors.EBI Universidad Complutense de Madrid
21669533 26 Optimisation of a novel series of selective CNS penetrant CB(2) agonists.EBI Pfizer Inc.
20971001 45 Indazole derivatives as novel bradykinin B1 receptor antagonists.EBI Merck Research Laboratories
21420857 115 Decahydroquinoline amides as highly selective CB2 agonists: role of selectivity on in vivo efficacy in a rodent model of analgesia.EBI Merck Research Laboratories
21376588 4 Discovery of indole alkaloids with cannabinoid CB1 receptor antagonistic activity.EBI Chiba University
21354795 95 1,4-Diazepane compounds as potent and selective CB2 agonists: optimization of metabolic stability.EBI Boehringer Ingelheim Pharmaceuticals
21420860 34 Imidazopyridine CB2 agonists: optimization of CB2/CB1 selectivity and implications for in vivo analgesic efficacy.EBI Merck Research Laboratories
21183257 202 Three-dimensional quantitative structure-selectivity relationships analysis guided rational design of a highly selective ligand for the cannabinoid receptor 2.EBI Universit£ degli Studi di Siena
20979417 83 4-Oxo-1,4-dihydropyridines as selective CB2 cannabinoid receptor ligands: structural insights into the design of a novel inverse agonist series.EBI Universite£? Lille-Nord de France
21115245 69 Structure-activity relationships of 2,4-diphenyl-1H-imidazole analogs as CB2 receptor agonists for the treatment of chronic pain.EBI Merck Research Laboratory
20943290 54 Synthesis and biological evaluation of new N-alkyl 1-aryl-5-(1H-pyrrol-1-yl)-1H-pyrazole-3-carboxamides as cannabinoid receptor ligands.EBI Sapienza Universit£ di Roma
21074998 80 Synthesis, binding studies and molecular modeling of novel cannabinoid receptor ligands.EBI German University in Cairo
20845959 94 Synthesis and biological evaluation of bivalent ligands for the cannabinoid 1 receptor.EBI Research Triangle Institute
20813948 63 Spiroindolones, a potent compound class for the treatment of malaria.EBI Swiss Tropical and Public Health Institute
20719511 17 Identification and hit-to-lead optimization of a novel class of CB1 antagonists.EBI Ligand Pharmaceuticals, Inc.
20688519 58 Two distinct classes of novel pyrazolinecarboxamides as potent cannabinoid CB1 receptor agonists.EBI Abbott Healthcare Products BV
20667724 2 Discovery of cannabinoid-1 receptor antagonists by virtual screening.EBI Korea Research Institute of Chemical Technology
20643546 10 Synthesis and cannabinoid-1 receptor binding affinity of conformationally constrained analogs of taranabant.EBI Merck Research Laboratories
20584609 13 Rational design of a novel peripherally-restricted, orally active CB(1) cannabinoid antagonist containing a 2,3-diarylpyrrole motif.EBI Sanofi-aventis R&D
20483606 71 Dihydro-pyrano[2,3-b]pyridines and tetrahydro-1,8-naphthyridines as CB1 receptor inverse agonists: synthesis, SAR and biological evaluation.EBI Merck Research Laboratories
20218623 68 Emerging targets in osteoporosis disease modification.EBI Amgen, Inc.
20423086 93 Discovery of N-[(4R)-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-2,2-dimethyl-3,4-dihydro-2H-pyrano[2,3-b]pyridin-4-yl]-5-methyl-1H-pyrazole-3-carboxamide (MK-5596) as a novel cannabinoid-1 receptor (CB1R) inverse agonist for the treatment of obesity.EBI Merck Research Laboratories
20096577 42 Furo[2,3-b]pyridine-based cannabinoid-1 receptor inverse agonists: synthesis and biological evaluation. Part 1.EBI Merck Research Laboratories
20137936 7 Radiosynthesis of novel carbon-11-labeled triaryl ligands for cannabinoid-type 2 receptor.EBI National Institute of Radiological Sciences
20047779 86 Discovery of benzhydrylpiperazine derivatives as CB1 receptor inverse agonists via privileged structure-based approach.EBI Chinese Academy of Sciences
19767206 9 Synthesis and in vitro autoradiographic evaluation of a novel high-affinity radioiodinated ligand for imaging brain cannabinoid subtype-1 receptors.EBI National Institute of Mental Health
20045337 117 Synthesis and structure-activity relationship of 1,2,4-triazole-containing diarylpyrazolyl carboxamide as CB1 cannabinoid receptor-ligand.EBI Green Cross Corporation
20022504 9 Synthesis and biological evaluation of new potential inhibitors of N-acylethanolamine hydrolyzing acid amidase.EBI University of Salerno
20189815 20 Synthesis and in vitro biological evaluation of carbon-11-labeled quinoline derivatives as new candidate PET radioligands for cannabinoid CB2 receptor imaging.EBI Indiana University School of Medicine
20079638 61 Synthesis and structure-activity relationship of substitutions at the C-1 position of Delta9-tetrahydrocannabinol.EBI AMRI
20015647 64 Conversion of 4-cyanomethyl-pyrazole-3-carboxamides into CB1 antagonists with lowered propensity to pass the blood-brain-barrier.EBI 7TM Pharma A/S
20005710 70 Non-aromatic A-ring replacement in the triaryl bis-sulfone CB2 receptor inhibitors.EBI Merck Research Laboratories
20005704 7 Novel thioamide derivatives as neutral CB1 receptor antagonists.EBI AstraZeneca R&D M£lndal
19954978 55 Exploring SAR features in diverse library of 4-cyanomethyl-pyrazole-3-carboxamides suitable for further elaborations as CB1 antagonists.EBI 7TM Pharma A/S
19919895 54 Novel sulfamoyl benzamides as selective CB(2) agonists with improved in vitro metabolic stability.EBI Adolor Corporation
20047331 30 Design, synthesis, biological properties, and molecular modeling investigations of novel tacrine derivatives with a combination of acetylcholinesterase inhibition and cannabinoid CB1 receptor antagonism.EBI Solvay Pharma
19921781 220 Indol-3-ylcycloalkyl ketones: effects of N1 substituted indole side chain variations on CB(2) cannabinoid receptor activity.EBI Abbott Laboratories
19743867 51 Discovery of 1-[4-(3-chlorophenylamino)-1-methyl-1H-pyrrolo[3,2-c]pyridin-7-yl]-1-morpholin-4-ylmethanone (GSK554418A), a brain penetrant 5-azaindole CB2 agonist for the treatment of chronic pain.EBI GlaxoSmithKline
19736007 31 Novel pyridine derivatives as potent and selective CB2 cannabinoid receptor agonists.EBI Adolor Corporation
19683918 36 Bioisosteric replacement of the hydrazide pharmacophore of the cannabinoid-1 receptor antagonist SR141716A. Part I: potent, orally-active 1,4-disubstituted imidazoles.EBI Pfizer Global Research and Development
19646869 54 Discovery of N-(3-(morpholinomethyl)-phenyl)-amides as potent and selective CB2 agonists.EBI Adolor Corporation
19632830 47 Synthesis and evaluation of N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-aminopropanamide as human cannabinoid-1 receptor (CB1R) inverse agonists.EBI Merck Research Laboratories
19699640 12 Synthesis and SAR of 1,4,5,6-tetrahydropyridazines as potent cannabinoid CB1 receptor antagonists.EBI Solvay Pharma
19500981 26 Rapid assessment of a novel series of selective CB(2) agonists using parallel synthesis protocols: A Lipophilic Efficiency (LipE) analysis.EBI Pfizer Discovery Chemistry
19515560 24 Fatty acid amide hydrolase inhibitors. Surprising selectivity of chiral azetidine ureas.EBI Vernalis (R&D) Ltd
19161308 4 Total synthesis of photoactivatable or fluorescent anandamide probes: novel bioactive compounds with angiogenic activity.EBI Universit£ de Montpellier I
 33 Structure activity relationships of tetrahydrocannabinol analogues on human cannabinoid receptorsEBI TBA
 38 New class of potent ligands for the human peripheral cannabinoid receptorEBI TBA
19530697 59 Discovery of 2-[5-(4-chloro-phenyl)-1-(2,4-dichloro-phenyl)-4-ethyl-1H-pyrazol-3-yl]-1,5,5-trimethyl-1,5-dihydro-imidazol-4-thione (BPR-890) via an active metabolite. A novel, potent and selective cannabinoid-1 receptor inverse agonist with high antiobesity efficacy in DIO mice.EBI National Health Research Institutes
19331413 54 New resorcinol-anandamide"hybrids" as potent cannabinoid receptor ligands endowed with antinociceptive activity in vivo.EBI Universita degli Studi di Siena
19328684 67 Pyridopyrimidine based cannabinoid-1 receptor inverse agonists: Synthesis and biological evaluation.EBI Merck Research Laboratories
19328683 22 Hair growth stimulator property of thienyl substituted pyrazole carboxamide derivatives as a CB1 receptor antagonist with in vivo antiobesity effect.EBI Zydus Research Centre
19320488 171 1-Sulfonyl-4-acylpiperazines as selective cannabinoid-1 receptor (CB1R) inverse agonists for the treatment of obesity.EBI Merck Research Laboratories
19250829 46 Quantitative structure-activity relationship (QSAR) for a series of novel cannabinoid derivatives using descriptors derived from semi-empirical quantum-chemical calculations.EBI St. Jude Children's Research Hospital
19230659 12 Design and synthesis of novel tri-aryl CB2 selective cannabinoid ligands.EBI University of Tennessee-Memphis
19095444 48 1,2,3-Triazole derivatives as new cannabinoid CB1 receptor antagonists.EBI National Central University
19091565 101 CB2 selective sulfamoyl benzamides: optimization of the amide functionality.EBI Adolor Corporation
19062274 72 Discovery of alpha-amidosulfones as potent and selective agonists of CB2: synthesis, SAR, and pharmacokinetic properties.EBI Amgen Inc
19053765 15 New analgesics synthetically derived from the paracetamol metabolite N-(4-hydroxyphenyl)-(5Z,8Z,11Z,14Z)-icosatetra-5,8,11,14-enamide.EBI Martin-Luther-Universitaet
18977140 43 2-Arylimino-5,6-dihydro-4H-1,3-thiazines as a new class of cannabinoid receptor agonists. Part 3: Synthesis and activity of isosteric analogs.EBI Shionogi & Co., Ltd
18831576 66 Tetrahydrolipstatin analogues as modulators of endocannabinoid 2-arachidonoylglycerol metabolism.EBI Sapienza Università di Roma
18754613 23 Discovery and labeling of high-affinity 3,4-diarylpyrazolines as candidate radioligands for in vivo imaging of cannabinoid subtype-1 (CB1) receptors.EBI National Institute of Mental Health
18712856 129 Bioisosteric replacement of the pyrazole 5-aryl moiety of N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716A). A novel series of alkynylthiophenes as potent and selective cannabinoid-1 receptor antagonists.EBI National Health Research Institutes
18640038 74 Structural modifications of N-arylamide oxadiazoles: Identification of N-arylpiperidine oxadiazoles as potent and selective agonists of CB2.EBI Amgen Inc.
18595717 2 Comparative molecular dynamics simulations of the potent synthetic classical cannabinoid ligand AMG3 in solution and at binding site of the CB1 and CB2 receptors.EBI The National Hellenic Research Foundation
18570365 29 The many roles for fluorine in medicinal chemistry.EBI Merck Research Laboratories
18524604 36 Exploring the substituent effects on a novel series of C1'-dimethyl-aryl Delta8-tetrahydrocannabinol analogs.EBI University of Tennessee-Memphis
18522867 149 Novel benzimidazole derivatives as selective CB2 agonists.EBI AstraZeneca R&D Montréal
18512901 27 Conformationally constrained analogues of N-(piperidinyl)-5-(4-chlorophenyl)-1-(2,4- dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716): design, synthesis, computational analysis, and biological evaluations.EBI Research Triangle Institute
18511157 15 Analogs of JHU75528, a PET ligand for imaging of cerebral cannabinoid receptors (CB1): development of ligands with optimized lipophilicity and binding affinity.EBI Johns Hopkins University School of Medicine
18342403 13 Rational design, synthesis and biological evaluation of new 1,5-diarylpyrazole derivatives as CB1 receptor antagonists, structurally related to rimonabant.EBI Università di Genova
18243711 76 Design, synthesis and biological evaluation of piperazine analogues as CB1 cannabinoid receptor ligands.EBI Central Research Institute
17582659 22 Synthesis and cannabinoid activity of 1-substituted-indole-3-oxadiazole derivatives: novel agonists for the CB1 receptor.EBI Monash University (Parkville Campus)
11678659 1 Antimalarial (+)-trans-hexahydrodibenzopyran derivatives from Machaerium multiflorum.EBI University of Mississippi
18255291 45 Arylsulfonamide CB2 receptor agonists: SAR and optimization of CB2 selectivity.EBI Evotec (UK) Ltd.
17979261 8 Diaryl dihydropyrazole-3-carboxamides with significant in vivo antiobesity activity related to CB1 receptor antagonism: synthesis, biological evaluation, and molecular modeling in the homology model.EBI Zydus Research Centre
17884494 79 New 1,2,3,4-tetrahydropyrrolo[3,4-b]indole derivatives as selective CB2 receptor agonists.EBI AstraZeneca R&D Montreal
17827022 16 Novel, potent THC/anandamide (hybrid) analogs.EBI Organix, Inc.
17643986 11 Sulfonamide derivatives as new potent and selective CB2 cannabinoid receptor agonists.EBI Taisho Pharmaceutical Co., Ltd
17608398 14 Discovery of N-{(1S,2S)-2-(3-cyanophenyl)- 3-[4-(2-[18F]fluoroethoxy)phenyl]-1-methylpropyl}- 2-methyl-2-[(5-methylpyridin-2-yl)oxy]propanamide, a cannabinoid-1 receptor positron emission tomography tracer suitable for clinical use.EBI TBA
17604171 20 Metabolically labile cannabinoid esters: a 'soft drug' approach for the development of cannabinoid-based therapeutic drugs.EBI Università di Pisa
17531479 65 2-Arylimino-5,6-dihydro-4H-1,3-thiazines as a new class of cannabinoid receptor agonists. Part 2: orally bioavailable compounds.EBI Shionogi & Co. Ltd
17521907 50 2-Arylimino-5,6-dihydro-4H-1,3-thiazines as a new class of cannabinoid receptor agonists. Part 1: discovery of CB2 receptor selective compounds.EBI Shionogi & Co., Ltd.
17521177 90 The application of 3D-QSAR studies for novel cannabinoid ligands substituted at the C1' position of the alkyl side chain on the structural requirements for binding to cannabinoid receptors CB1 and CB2.EBI The National Hellenic Research Foundation
17513109 32 Discovery of pyrazine carboxamide CB1 antagonists: the introduction of a hydroxyl group improves the pharmaceutical properties and in vivo efficacy of the series.EBI Pharmaceutical Research Institute
17507224 82 Biaryl cannabinoid mimetics--synthesis and structure-activity relationship.EBI Adolor Corporation
17466519 39 Optimization of triaryl bis-sulfones as cannabinoid-2 receptor ligands.EBI Schering-Plough Research Institute
17433696 38 Scaffold hopping, synthesis and structure-activity relationships of 5,6-diaryl-pyrazine-2-amide derivatives: a novel series of CB1 receptor antagonists.EBI AstraZeneca R&D Mölndal
17383180 52 Optimization of imidazole amide derivatives as cannabinoid-1 receptor antagonists for the treatment of obesity.EBI Bayer HealthCare
17293109 69 Substituted acyclic sulfonamides as human cannabinoid-1 receptor inverse agonists.EBI Merck Research Laboratories
17270441 72 Lead optimization of 5,6-diarylpyridines as CB1 receptor inverse agonists.EBI Merck Research Laboratories
17110113 2 Synthesis and biological evaluation of several structural analogs of 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand.EBI Teikyo University
17107792 38 Constrained analogs of CB-1 antagonists: 1,5,6,7-Tetrahydro-4H-pyrrolo[3,2-c]pyridine-4-one derivatives.EBI Bayer HealthCare
17004712 18 Biarylpyrazole inverse agonists at the cannabinoid CB1 receptor: importance of the C-3 carboxamide oxygen/lysine3.28(192) interaction.EBI University of North Carolina Greensboro
16682198 4 Synthesis of a potential photoactivatable anandamide analog.EBI Université Montpellier 1
16570929 29 Oxyhomologues of anandamide and related endolipids: chemoselective synthesis and biological activity.EBI Farmaceutiche
16392798 46 Synthesis and in vivo validation of [O-methyl-11C]2-{4-[4-(7-methoxynaphthalen-1-yl)piperazin- 1-yl]butyl}-4-methyl-2H-[1,2,4]triazine-3,5-dione: a novel 5-HT1A receptor agonist positron emission tomography ligand.EBI Columbia University College of Physicians and Surgeons
16263284 36 Synthesis of functionalized 1,8-naphthyridinones and their evaluation as novel, orally active CB1 receptor inverse agonists.EBI Merck Research Laboratories
16263283 55 New bicyclic cannabinoid receptor-1 (CB1-R) antagonists.EBI Pfizer Global Research and Development-Groton Laboratories
15801840 19 Substituted 5,5'-diphenyl-2-thioxoimidazolidin-4-one as CB1 cannabinoid receptor ligands: synthesis and pharmacological evaluation.EBI Université catholique de Louvain
15713403 40 Synthesis and activity of 4,5-diarylimidazoles as human CB1 receptor inverse agonists.EBI Merck Research Laboratories
15664857 24 Triaryl bis-sulfones as a new class of cannabinoid CB2 receptor inhibitors: identification of a lead and initial SAR studies.EBI Schering-Plough Research Institute
15664830 64 Synthesis and SAR of 5,6-diarylpyridines as human CB1 inverse agonists.EBI Merck Research Laboratories
14980654 26 Potent imidazole and triazole CB1 receptor antagonists related to SR141716.EBI Neurocrine Biosciences Inc.
14736243 49 Synthesis, biological properties, and molecular modeling investigations of novel 3,4-diarylpyrazolines as potent and selective CB(1) cannabinoid receptor antagonists.EBI Solvay Pharma
14613317 14 An aromatic microdomain at the cannabinoid CB(1) receptor constitutes an agonist/inverse agonist binding region.EBI Forbes Norris ALS/MDA Research Center
14505654 14 Synthesis and testing of novel phenyl substituted side-chain analogues of classical cannabinoids.EBI University of Tennessee-Memphis
12166938 8 Conformational memories and the endocannabinoid binding site at the cannabinoid CB1 receptor.EBI Kennesaw State University
12161142 34 C-3 Amido-indole cannabinoid receptor modulators.EBI Bristol-Myers Squibb
11020293 42 Novel cannabinol probes for CB1 and CB2 cannabinoid receptors.EBI Organix, Inc.
10633038 36 QSAR analysis of Delta(8)-THC analogues: relationship of side-chain conformation to cannabinoid receptor affinity and pharmacological potency.EBI Research Triangle Institute
9379452 8 Importance of the C-1 substituent in classical cannabinoids to CB2 receptor selectivity: synthesis and characterization of a series of O,2-propano-delta 8-tetrahydrocannabinol analogs.EBI Kennesaw State University
8831752 9 Synthesis and pharmacology of a very potent cannabinoid lacking a phenolic hydroxyl with high affinity for the CB2 receptor.EBI Clemson University
27305312 4 Capture-Tag-Release: A Strategy for Small Molecule Labeling of Native Enzymes.BDB Fairfield University
27113261 12 2-Prenylated m-dimethoxybenzenes as potent inhibitors of 15-lipo-oxygenase: inhibitory mechanism and SAR studies.BDB Ferdowsi University of Mashhad
27376460 5 Synthesis, anti-inflammatory, analgesic, 5-lipoxygenase (5-LOX) inhibition activities, and molecular docking study of 7-substituted coumarin derivatives.BDB Nirma University
26808391 6 A Dual Non-ATP Analogue Inhibitor of Aurora Kinases A and B, Derived from Resorcinol with a Mixed Mode of Inhibition.BDB Jawaharlal Nehru Centre for Advanced Scientific Research
26833890 18 Synthesis, Biological Evaluation, and Molecular Docking of 8-imino-2-oxo-2H,8H-pyrano[2,3-f]chromene Analogs: New Dual AChE Inhibitors as Potential Drugs for the Treatment of Alzheimer's Disease.BDB Yogi Vemana University
26575582 15 Development of 2-(Substituted Benzylamino)-4-Methyl-1, 3-Thiazole-5-Carboxylic Acid Derivatives as Xanthine Oxidase Inhibitors and Free Radical Scavengers.BDB Jamia Hamdard
26469307 7 Phosphorylation of Capsaicinoid Derivatives Provides Highly Potent and Selective Inhibitors of the Transcription Factor STAT5b.BDB University of Leipzig
12235229 26 Lithocholylcholine, a bile acid/acetylcholine hybrid, is a muscarinic receptor antagonist.BDB University of Arkansas
20827790 21 A novel competitive class of ╬▒-glucosidase inhibitors: (E)-1-phenyl-3-(4-styrylphenyl)urea derivatives.BDB Gyeongsang National University
8730737 23 Effects of the 5-HT2B receptor agonist, BW 723C86, on three rat models of anxiety.BDB SmithKline Beecham Pharmaceuticals
8667026 14 The C-terminal domain of the mGluR1 metabotropic glutamate receptor affects sensitivity to agonists.BDB CNS Research
8022403 113 A binding site model and structure-activity relationships for the rat A3 adenosine receptor.BDB National Institute of Diabetes, Digestive and Kidney Diseases
19385613 60 Human glucagon receptor antagonists with thiazole cores. A novel series with superior pharmacokinetic properties.BDB Novo Nordisk A/S
17467988 21 Novel glucocorticoids containing a 6,5-bicyclic core fused to a pyrazole ring: synthesis, in vitro profile, molecular modeling studies, and in vivo experiments.BDB Merck Research Laboratories
17125251 20 A 2.13 A structure of E. coli dihydrofolate reductase bound to a novel competitive inhibitor reveals a new binding surface involving the M20 loop region.BDB University of Prince Edward Island
17201405 9 Development of dihydropyridone indazole amides as selective rho-kinase inhibitors.BDB GlaxoSmithKline
8894098 20 Discovery and optimization of nonpeptide HIV-1 protease inhibitors.BDB Parke-Davis Pharmaceutical Research
17393456 4 Identification of novel fragment compounds targeted against the pY pocket of v-Src SH2 by computational and NMR screening and thermodynamic evaluation.BDB University College London
8164260 23 The development of cyclic sulfolanes as novel and high-affinity P2 ligands for HIV-1 protease inhibitors.BDB Merck Research Laboratories
2200122 1 Design, activity, and 2.8 A crystal structure of a C2 symmetric inhibitor complexed to HIV-1 protease.BDB Abbott Laboratories